Peptide Vectors for Blood-Brain Barrier Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for delivering therapeutic molecules across the blood-brain barrier (BBB) are inefficient, as 98% of potential drugs fail to cross due to the barrier's impermeability, limiting treatment options for central nervous system (CNS) disorders.
Innovation Solution
Development of optimized peptides or pseudo-peptides that bind to the human low-density lipoprotein receptor (hLDLR), allowing for the transport of large molecules across the BBB through receptor-mediated transcytosis, enhancing bioavailability and targeting to the CNS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the BBB maintains its natural impermeability to protect the brain, then brain homeostasis is maintained, but therapeutic molecules cannot cross into the CNS
Solution Approach 1:
The patent uses a peptide vector as an intermediary that binds to the LDLR receptor on BBB endothelial cells. This peptide acts as a mediator that facilitates the transport of therapeutic molecules across the BBB without compromising the barrier's protective function. The peptide-receptor complex enables selective passage of therapeutic agents while the BBB maintains its integrity against other substances.
Solution Approach 2:
The invention extracts and utilizes the LDLR receptor-mediated transcytosis pathway from the natural BBB transport mechanisms. By harnessing this specific extraction pathway, the patent enables selective transport of therapeutic molecules through the BBB while leaving the overall barrier impermeability intact, thus maintaining brain homeostasis while enabling drug delivery.
2Productivity
If the BBB allows increased permeability to enable drug transport, then therapeutic molecules can reach the CNS, but brain protection and homeostasis are compromised
Solution Approach 1:
The patent applies local quality by enabling selective transport at specific locations (endothelial cells expressing LDLR) without affecting the overall BBB structure. The peptide vector locally interacts with LDLR receptors to facilitate drug transport, while the rest of the BBB maintains its protective impermeability, thus achieving localized drug delivery without compromising global brain homeostasis.
Solution Approach 2:
The invention changes the parameter of permeability locally and temporarily through receptor-mediated transcytosis. The BBB's permeability is dynamically adjusted by utilizing the LDLR pathway - it remains impermeable to most substances but becomes selectively permeable to peptide-conjugated therapeutic molecules, achieving controlled parameter change that enables drug transport while maintaining overall protection.
3Productivity
If small lipophilic molecules are used to cross the BBB, then transport is achieved, but therapeutic efficacy is limited due to molecular size constraints
Solution Approach 1:
The peptide vector serves as an intermediary carrier that enables large therapeutic molecules (peptides, proteins, antibodies) to cross the BBB. Instead of relying on the molecule's own lipophilic properties, the peptide mediator binds to LDLR and transports the conjugated therapeutic cargo through transcytosis, thereby overcoming the size limitation that prevents large molecules from crossing the BBB via passive diffusion.
Solution Approach 2:
The patent replaces the mechanical/physical system of passive diffusion (which is limited to small lipophilic molecules) with a biological transport system based on receptor-mediated endocytosis and transcytosis. This substitution of transport mechanism allows large therapeutic molecules to cross the BBB by utilizing the cellular uptake machinery of LDLR, bypassing the size and lipophilicity constraints of passive diffusion.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptides effectively facilitate the passage of therapeutic, diagnostic, or imaging agents across the BBB, improving their bioavailability and targeting to the CNS, overcoming the barrier's impermeability and enhancing treatment options for CNS disorders.
Implementation Method 1
optimized peptides or pseudo-peptides that bind to the human low-density lipoprotein receptor (hLDLR), allowing for the transport of large molecules across the BBB through receptor-mediated transcytosis
Data Source
Figure 1
Figure 2a~2b
Figure 3A~3B
AI summary
The invention relates to peptide derivatives (peptides and pseudo-peptides) and to the use thereof as vectors for molecules of interest. The invention also relates to conjugates containing a peptide derivative of the invention bonded to a molecule of interest. The peptides of the invention can be used for delivering, in the form of conjugates, generally prodrugs, molecules of pharmaceutical or diagnostic interest, for instance therapeutic molecules, imaging or diagnostic agents or molecular probes, across cell membranes, and in particular for promoting transport thereof across the blood-brain barrier (BBB).